The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials
2007

Impact of Topiramate on Daily Activities in Migraine Patients

Sample size: 756 publication Evidence: high

Author Information

Author(s): Carl Dahlöf, Elizabeth Loder, Merle Diamond, Marcia Rupnow, George Papadopoulos, Lian Mao

Primary Institution: Gothenburg Migraine Clinic

Hypothesis

Does topiramate improve daily activities and patient functioning in migraine patients?

Conclusion

Topiramate significantly improved daily activities and patient functioning for those achieving a 50% reduction in migraine frequency.

Supporting Evidence

  • Topiramate 100 mg/d significantly improved Migraine-Specific Questionnaire scores versus placebo.
  • Patients on topiramate had significantly less migraine-related disruption of daily activities.
  • 46% of topiramate-treated patients were ≥ 50% responders compared to 23% on placebo.

Takeaway

Taking topiramate helps people with migraines feel better and do more things every day.

Methodology

Pooled analyses of data from three randomized, double-blind, placebo-controlled trials assessing the effects of topiramate on migraine frequency and daily activities.

Potential Biases

Potential bias due to the nature of the trials and the reporting of self-reported outcomes.

Limitations

The study may not fully assess the impact of adverse events of drug treatment.

Participant Demographics

Mean age 39.8 years, 86% female, predominantly Caucasian.

Statistical Information

P-Value

p < 0.001

Statistical Significance

p < 0.001

Digital Object Identifier (DOI)

10.1186/1477-7525-5-56

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication